Table 1 RNA expression of T-cell priming markers among diverse cancers (N = 514) (see Supplemental Table 1 for functions).

From: T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

T-cell priming markers

Mean RNA expression (range)a

Low RNA expression

N (%)a

Intermediate RNA expression

N (%)a

High RNA expression

N (%)a

CD27

45.2 (0–99)

150 (29.1%)

266 (51.8%)

98 (19.1%)

CD28

43.4 (0–100)

154 (30.0%)

258 (50.2%)

102 (19.8%)

CD40

46.1 (0–100)

153 (29.8%)

247 (48.1%)

114 (22.2%)

CD40LG

43.4 (0–100)

164 (31.9%)

246 (47.9%)

104 (20.2%)

CD80

48.4 (0–99)

126 (24.5%)

273 (53.1%)

115 (22.4%)

CD86

43.0 (0–99)

154 (30.0%)

276 (53.7%)

84 (16.3%)

CD137

41.1 (0–99)

169 (32.9%)

268 (52.1%)

77 (15.0%)

GITR

45.9 (0–99)

147 (28.6%)

268 (52.1%)

99 (19.3%)

GZMB

42.2 (0–99)

178 (34.6%)

251 (48.8%)

85 (16.5%)

ICOS

35.4 (0–99)

226 (44.0%)

218 (42.4%)

70 (13.6%)

ICOSLG

59.7 (0–100)

76 (14.8%)

246 (47.9%)

192 (37.4%)

IFNG

29.9 (0–100)

257 (50.0%)

206 (40.1%)

51 (9.9%)

OX40

50.6 (0–100)

106 (20.6%)

286 (55.6%)

122 (23.7%)

OX40LG

44.4 (0–99)

170 (33.1%)

225 (43.8%)

119 (23.2%)

TBX21

41.7 (0–99)

183 (35.6%)

244 (47.5%)

87 (16.9%)

  1. The expression profiles were stratified by rank values into “Low” (0–24), “Intermediate” (25–74), and “High” (75–100) percentile.
  2. Percentage indicates percent of patients with that rank, e.g., 29.1% of patients showed low RNA expression of CD27 in their tumors
  3. See Methods as well.
  4. CD Cluster of differentiation, GITR Glucocorticoid-Induced TNFR-Related, GZMB Granzyme B, ICOS Inducible T Cell Costimulator, IFNG Interferon-gamma, LG ligand, TBX T-Box Transcription Factor.
  5. aTranscript abundance was normalized to internal housekeeping gene profiles and ranked (0–100) to standardized by internal a reference population of 735 tumors spanning 35 histologies.
Back to article page